BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Friday, September 4, 2026
📌TL;DR
Ivonescimab monotherapy showed a statistically significant overall survival benefit versus pembrolizumab monotherapy in HARMONi-2, Akeso's Chinese Phase 3 in first line PD-L1 positive NSCLC; no effect sizes were disclosed; SMMT closed up 17.3 percent.
Ultragenyx's apazunersen (GTX-102) failed Phase 3 Aspire in Angelman syndrome on the primary and key secondary endpoints; the company will make significant expense reductions; RARE lost 44.0 percent.
GSK licensed Hutchmed's preclinical KRAS conjugate HMPL-A830 for $110 million upfront and up to $1.295 billion total plus tiered royalties, worldwide outside Greater China; Hutchmed's US ADRs rose 17.2 percent.
AbbVie's etentamig hit Phase 3 CERVINO in relapsed multiple myeloma with full numbers at topline: 74.0 versus 45.7 percent response, 0.40 progression free survival hazard ratio; ABBV closed down 0.6 percent.
Released FDA documents show the primary review team recommended rejecting Replimune's Tudriqev a third time before a CBER director overruled them citing the 10 to 3 advisory vote, per BioSpace.
The week's delivered catalyst tally closed at 1 of 13: one sponsor closed higher across thirteen dated catalysts delivered since last Friday.
⚡ Executive Takeaway
On Monday we set one job for this week: count what delivered catalysts pay. The count is done. Thirteen dated, promised events arrived on schedule between last Friday and tonight, and exactly one sponsor closed higher on delivery day. That is not a market punishing bad news, because twelve of the thirteen were wins or neutral outcomes. It is a market that had already paid for the headline and then read the label.
Look at who did get paid this week and the rule writes itself. Every positive close in our no numbers series, Jazz, Novartis, Teva, and now Summit's 17 percent, came on a release that declared direction and withheld magnitude. AbbVie printed a complete win, every number at topline, and closed lower. Alumis and Ultragenyx printed misses and lost roughly half. Disclosure is not neutral. Detail collapses the range of stories a stock can tell, and the market pays for the range, not the story. Underwrite the label, not the headline, and treat every withheld number as a second catalyst you have not yet been charged for.
🥊 Oncology
Ivonescimab beat Keytruda on survival, and kept the number in its pocket. SMMT
Summit Therapeutics and Akeso said ivonescimab monotherapy produced a statistically significant overall survival benefit versus pembrolizumab monotherapy in HARMONi-2, the Chinese Phase 3 in first line PD-L1 positive non small cell lung cancer that made the drug famous with a 0.51 progression free survival hazard ratio in 2024. No hazard ratio, medians, or p value this time; the analysis goes to an upcoming medical conference. A 2025 interim had shown only a positive trend, so crossing into significance is the news. SMMT closed at $17.13, up 17.3 percent, the largest positive close in our no numbers series and its seventh member. Keep clear what this is not: the US application, due a decision November 14, rests on the separate HARMONi trial in EGFR mutated disease, where the survival benefit has never reached protocol significance.
🧬 Rare Disease
Ultragenyx's Angelman program hit the wall, two weeks before its bigger date. RARE
Apazunersen (GTX-102) failed Phase 3 Aspire on both the Bayley-4 cognitive primary endpoint and the Multidomain Responder Index key secondary, with the release stating there were no differences between treated and control groups and printing no effect sizes. Ultragenyx will decide the program's disposition and, more consequentially, will define and implement what it calls significant expense reductions. RARE lost 44.0 percent to $14.85, the second largest single day loss we have logged this quarter after Alumis. The date that matters now is September 19, when the FDA rules on UX111 in Sanfilippo syndrome type A, an unrelated program sitting on the same suddenly smaller balance sheet.
🤝 Deals
GSK paid the richest preclinical cash share in our ledger for Hutchmed's KRAS conjugate. GSK | HCM | PFE
GSK licensed HMPL-A830, an anti EGFR antibody carrying a selective KRAS inhibitor payload, for $110 million upfront and up to $1.295 billion total plus tiered royalties, worldwide outside Greater China. The asset has not dosed a patient; Hutchmed leads a first trial starting in the second half of 2026. At 8.5 percent cash share of the headline, GSK paid nearly double the 4.9 percent Roche handed Simcere for a preclinical trispecific a week ago. The same day showed the market's other end: Pfizer moved a discontinued Phase 1 Seagen ADC, PF-08046031, to Medicus Pharma for $12 million upfront against more than $1 billion in milestones, per Fierce Biotech. Hot preclinical mechanism, 8.5 percent cash up front; shelved clinical asset, about one. Hutchmed's US ADRs rose 17.2 percent to $14.11.
🩸 Hematology
AbbVie printed every number at topline, and the market shrugged. ABBV
Etentamig, AbbVie's BCMA directed bispecific T cell engager, beat investigator's choice therapy in the Phase 3 CERVINO trial in triple class exposed relapsed or refractory multiple myeloma: objective response 74.0 versus 45.7 percent, progression free survival hazard ratio 0.40, twelve month survival 87.9 versus 72.0 percent, cytokine release syndrome in 28.3 percent with nothing above grade 2 reported, all disclosed in the topline release. Full data land September 25 and AbbVie goes to regulators next. ABBV closed down 0.6 percent. Set this beside Summit's day and the asymmetry we published Tuesday is the cleanest it has ever been: complete disclosure earned a shrug, and the withheld number earned 17 percent.
🏛️ FDA
The review team said reject Tudriqev a third time. One director said approve. REPL
Newly released FDA documents show the agency's primary reviewers concluded Replimune had not fixed the deficiencies from two complete response letters and headed for a third rejection, per BioSpace's reading. A director at the Center for Biologics Evaluation and Research overruled them in an August 6 memo citing the 10 to 3 advisory committee vote, the totality of evidence, and confirmation to come from the ongoing IGNYTE-3 trial. BioSpace did not name the director and neither will we. When the approval landed we wrote that hostile briefing documents create variance, not verdicts. The documents now show where the verdict actually lived: one level above the people who wrote the briefing, in the same improvising agency that reversed itself on uniQure between November and June.
🩻 Medtech
Medtech woke up: surgical robots, a warning letter, and two more cyber disclosures. MDT | BSX | SYK
Medtronic confirmed a strategic partnership with Hong Kong surgical robotics maker Cornerstone Robotics, an investment reported at about $700 million by MedTech Dive; MDT added 1.0 percent. Stryker agreed to buy ZuriMED for rotator cuff repair technology, Enovis is taking over eCential Robotics for orthopedic surgical robots, and Fresenius Medical Care took an FDA warning letter over a Utah facility's complaint trend, per Fierce Pharma. On the cyber ledger, NovoCure disclosed that an attack exposed patient data and DaVita settled breach claims for a reported $15 million. Boston Scientific ended the week it had promised partial shipping restoration with no public update since Monday night as of Thursday evening; BSX fell 2.9 percent, market data, no cause assigned.
📋 Quick Hits
Amgen's VESALIUS-CV mortality data from ESC (August 31 release, published in Circulation): Repatha cut the risk of death by 20 percent in high risk primary prevention over a median 4.6 years; Amgen's chief medical officer called it a potential inflection point, per Fierce Pharma.
Roche told Fierce Biotech it is excited about its UCN2 analog for weight loss that preserves muscle, its second muscle preserving obesity bet after the up to $2.3 billion Hanmi deal.
Amylyx logged a fifth consecutive close below its $35.50 offer price at $33.96; the $500.2 million offering's closing remained unannounced as of Thursday evening, and the greenshoe window forces disclosure by roughly September 18.
Day two moves: TScan slipped 2.7 percent to $0.3709 with no partnering news; uniQure eased 3.0 percent to $44.86 after Wednesday's BLA filing.
Lilly's purchase of Sangamo's platforms is expected to close today, Friday September 4; no closing announcement had appeared as of Thursday evening.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full ivonescimab data history in one table: HARMONi-2 PFS and OS, all three HARMONi survival cuts, and HARMONi-A
The GSK and Hutchmed terms table with the cash share math, and the Pfizer and Medicus barbell on the same day
The complete CERVINO results, including the safety lines the topline actually disclosed
The week's delivered catalyst log day by day, and Thursday's sixteen ticker closes table
📋 The Week in Review
Monday: the White House announced nine more MFN pricing agreements with no midsize alliance member among them; Lilly bought Merida for up to $2.875 billion; the week's delivered catalyst count opened at 1 of 7.
Tuesday: Novartis paused eight autoimmune CAR T trials after three deaths and BMS paused zola-cel enrollment; Roche paid $75 million upfront for Simcere's B cell trispecific; Alumis printed its lupus miss and lost 56.6 percent.
Wednesday: TScan cut about 75 percent of staff and put its autoimmune program up for partnering; Novartis signed the royalty inclusive up to $3.2 billion Alteogen deal; uniQure filed the first Huntington's gene therapy BLA.
Thursday: ivonescimab's overall survival win over Keytruda in China; Ultragenyx's Angelman failure and coming expense cuts; GSK's $110 million upfront Hutchmed bet; AbbVie's full disclosure CERVINO win; the tally closed at 1 of 13.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The 1 of 13 ledger closed: what the only winning delivery of the week had in common with the other three positive closes we logged, and the two part rule for every dated event left this quarter
💊 What Summit's China win is actually worth on November 14: the three things an overall survival headline from the wrong trial changes about a PDUFA, and the one thing it cannot touch
📊 The 8.5 percent solution: what GSK's cash share says about where preclinical scarcity now prices, and why Pfizer's one percent deal on the same day is the same signal read backwards
🎯 Plus the full catalyst calendar, with the Angelman disposition and CERVINO's September 25 date added and the week's tally retired
Thirteen catalysts delivered, one paid. The only sellers of certainty who got paid this week were the ones who kept the number in their pocket. US markets are closed Monday for Labor Day; we will be back with the weekend swept. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →